Get started
Author

Ekaterina A. Dokukina

Observed names: E. A. Dokukina, E. Dokukina, E.A. Dokukina Dokukina, Ekaterina Dokukina, Докукина Е.А.
Institution: BIOCAD (Russia)
Observed institutions: R-Pharm (Russia), BIOCAD (Russia)
ORCID: 0000-0002-6759-673X
Observed ORCID: 0000-0002-6759-673X
OpenAlex ID: A5038473161
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
2021 · Nikita V. Lomakin, Bulat A. Bakirov, et al. · Inflammation Research · 58
PDF
Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
2021 · V. I. Mazurov, E. G. Zotkin, et al. · Rheumatology Science and Practice · 18
PDF
Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)
2021 · V. I. Mazurov, M. A. Korolev, et al. · Modern Rheumatology Journal · 14
PDF
A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study
2019 · Alexander M. Lila, Vadim I. Mazurov, et al. · Rheumatology International · 12
OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study
2018 · V. Mazurov, S. Erdes, et al. · Annals of the Rheumatic Diseases · 10
PDF
Op0226 Netakimab Decreases Disease Activity in Patients With Psoriatic Arthritis: Results From a Randomized Double-blind Phase 3 Clinical Trial (patera)
2020 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 6
PDF
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR
2024 · V. I. Mazurov, E. L. Nasonov, et al. · Doklady Biochemistry and Biophysics · 5
Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR
2023 · V. I. Mazurov, A. M. Lila, et al. · Rheumatology Science and Practice · 5
PDF
Fri0114 Efficacy of Levilimab, Novel Monoclonal Anti-il-6 Receptor Antibody, in Combination With Methotrexate in Patients With Rheumatoid Arthritis: 1-year Results of Phase 2 Aurora Study
2020 · V. Mazurov, E. Zotkin, et al. · Annals of the Rheumatic Diseases · 4
PDF
Fri0108 Short-term Efficacy of Bcd-089, Novel Monoclonal Anti-il-6 Receptor Antibody, in Combination With Methotrexate in Patients With Rheumatoid Arthritis: 12-week Results of Phase 2 Aurora Study
2019 · V Mazurov, Evgeniy Zotkin, et al. · Annals of the Rheumatic Diseases · 4
PDF
Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression
2023 · D. S. Fomina, S. S. Andreev, et al. · PULMONOLOGIYA · 3
PDF
Pos0624 Efficacy and Safety of Levilimab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis: Phase Iii, Double-blind, Placebo-controlled, Randomized Trial
2021 · V. Mazurov, M. Korolev, et al. · Annals of the Rheumatic Diseases · 3
PDF
Fri0391 Netakimab Improves Patient-related Outcomes in Patients With Radiological Axial Spondyloarthritis: Results From Randomised Phase 3 Trial (astera)
2019 · Inna Gaydukova, V Mazurov, et al. · Annals of the Rheumatic Diseases · 3
PDF
SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers
2018 · P. Khlyabova, A. Eremeeva, et al. · Annals of the Rheumatic Diseases · 2
PDF
THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study
2018 · A. Lila, L. Denisov, et al. · Annals of the Rheumatic Diseases · 2
PDF
Pos1214 the Dynamics of Inflammatory Markers in Covid-19 Patients Treated With Levilimab
2021 · N. Lomakin, B. Bakirov, et al. · Annals of the Rheumatic Diseases · 1
PDF
Ab0792 Netakimab Improves Patient-reported Outcomes in Patients With Psoriatic Arthritis: Results From a Randomized Double-blind Phase 3 Trial (patera)
2020 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 1
Fri0346 Efficacy of Netakimab in the Treatment of Axial Disease in Patients With Psoriatic Arthritis: Results of Subanalysis From a Double-blind Randomized Phase 3 Trial (patera)
2020 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 1
PDF
Ab0791 Netakimab Reduces Skin Manifestations of Psoriatic Arthritis: Results of Subanalysis From a Double-blind Randomized Phase 3 Study (patera)
2020 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 1
PDF
SAT0206 Results of the alterra clinical trial – the efficacy of the alternative dosing regimen for rituximab biosimilar in bdmards naive patients with rheumatoid arthritis
2018 · V. Mazurov, L. Denisov, et al. · Annals of the Rheumatic Diseases · 1
PDF
SAT0267 Efficacy and safety of bcd-055, proposed infliximab biosimilar, compared to infliximab: 54-week results from asart-2 phase 3 clinical study
2018 · L. Denisov, P. Shesternya, et al. · Annals of the Rheumatic Diseases · 1
PDF
Efficacy and safety of the first russian original long-acting erythropoiesis-stimulating agent for the treatment of anemia in patients with chronic renal failure. The results of the international multicenter randomized phase II clinical trial
2019 · V.IU. Shilo Shilo, L.I. Alihanova Alihanova, et al. · Kliničeskaâ nefrologiâ
The first russian darbepoetin alfa bioanalogue: results of a double-blind, randomized clinical study of efficacy and safety for patients with nephrogenic anemia on programmed hemodialysis
2018 · V.Yu. Shilo Shilo, V.P. Babich Babich, et al. · Kliničeskaâ nefrologiâ
Works count: 24
Citation count: 155
H-index: 6
I10-index: 5
Year
Topic
Type